These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24614711)

  • 1. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
    Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
    Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
    Anforth RM; Carlos GR; Scolyer RA; Chou S; Fernandez-Peñas P
    Melanoma Res; 2015 Feb; 25(1):91-4. PubMed ID: 25380183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
    Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
    Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
    Menzies AM; Haydu LE; Visintin L; Carlino MS; Howle JR; Thompson JF; Kefford RF; Scolyer RA; Long GV
    Clin Cancer Res; 2012 Jun; 18(12):3242-9. PubMed ID: 22535154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.
    Marin C; Beauchet A; Capper D; Zimmermann U; Julié C; Ilie M; Saiag P; von Deimling A; Hofman P; Emile JF
    Arch Pathol Lab Med; 2014 Jan; 138(1):71-5. PubMed ID: 23651150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
    Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
    Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of cell-free circulating BRAF
    Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
    Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the BRAF V600E mutation in primary cutaneous melanoma.
    Inumaru JS; Gordo KI; Fraga Junior AC; Silva AM; Leal CB; Ayres FM; Wastowski IJ; Borges NF; Saddi VA
    Genet Mol Res; 2014 Jan; 13(2):2840-8. PubMed ID: 24535907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
    Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
    Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrapatient homogeneity of BRAFV600E expression in melanoma.
    Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
    Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
    Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational status of naevus-associated melanomas.
    Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
    Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.